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Introduction Patients with primary Sj¨ ogren’s syndrome (pSS) are reported to have a variety of
gastrointestinal symptoms partly attributed to an overrepresentation of celiac disease. We
have observed that irritable bowel syndrome (IBS)-like symptoms are frequent complaints in
this patient group. Allergic manifestations to various drugs are also common in pSS. A role of
food allergy in IBS has been proposed.
Objective This study is aimed at evaluating the mucosal response to rectal challenge with
cow’s milk protein (CM) in patients with pSS and relates possible CM reactivity to their
intestinal symptoms.
Methods A rectal challenge with CM was performed in 21 patients with pSS and 18 healthy
controls. Fifteen hours after challenge the mucosal production of nitric oxide (NO) and the
release of myeloperoxidase (MPO) as signs of mucosal inﬂammatory reaction were measured
using the mucosal patch technique.
Results Eight out of 21 patients with pSS had a deﬁnite increase of mucosal NO synthesis and
the luminal release of MPO after rectal CM challenge. This sign of milk sensitivity was not
linked to IgG/IgA antibodies to milk proteins. The symptoms for IBS according to Rome III
criteria were fulﬁlled in13 patients.All patients who were CM sensitive suffered from IBS.In a
small open study, patients reactive to CM reported an improvement of intestinal symptoms on
a CM-free diet.
Conclusion A rectal mucosal inﬂammatory response after CM challenge is seen in 38% of
patients with pSS as a sign of CM sensitivity. IBS-like symptoms were common in pSS, linked
to CM sensitivity.
Keywords cow’s milk protein, food allergy, irritable bowel syndrome, myeloperoxidase,
nitrogen oxide, primary Sj¨ ogren’s syndrome
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Introduction
Primary Sj¨ ogren’s syndrome (pSS) is an autoimmune
disease characterized by the sicca complex due to lym-
phocytic inﬁltration of primarily the lacrimal and salivary
glands, resulting in keratoconjunctivitis sicca and xeros-
tomia [1]. Sicca symptoms may also appear in, e.g. the
skin and trachea due to affection of other exocrine glands.
General accompanying symptoms are fatigue, myalgia
and arthralgia. Gastrointestinal symptoms are also fre-
quent and include dysphagia, impaired pancreatic func-
tion, gastric antral inﬂammation and atrophy and
autoimmune liver disease [2]. In contrast, reports on small
bowel and colonic manifestations are rare but include
nutritional deﬁciencies due to malabsorption, possibly
due to associated celiac disease (CD) [3]. However, histo-
logical examinations have demonstrated increased
amounts of intra-epithelial lymphocytes in the mucosa of
pSS patients [4]. We ourselves have observed a high
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Editor’s Choiceincidence of reported intestinal symptoms and in particu-
lar diarrhoea in our pSS patients.
A high prevalence (65%) of various allergic manifesta-
tions and in particular allergic drug reactions (46%) have
been reported previously in pSS patients [5, 6]. In this
study, we have raised the question of whether their
intestinal complaints may possibly also reﬂect an allergic
manifestation. Up to 20–30% of the adult general popula-
tion in different European countries report self-experi-
enced adverse food reactions [7–10]. However, using
objective measures like dietary exclusion and a controlled
food antigen challenge, the prevalence of food allergy and
food intolerance is estimated to be much less frequent
[7, 9–11]. In food allergy, skin and laboratory tests may
detect the presence of IgE-mediated reactions particularly
in patients with asthma or eczema especially where the
foods are highly allergenic like egg, ﬁsh, nuts and milk.
However, many patients with proven food intolerance
have negative tests, suggesting other mechanisms than
those mediated by IgE. Unfortunately, the tests available
for non-IgE reactions are unreliable. Elimination diets and
placebo-controlled challenge with suspected antigens
have until now been the only established way to identify
non-IgE adverse food reactions [11].
The recently described mucosal patch technique, which
enables simultaneous measurements of nitric oxide (NO)
and soluble mediators like myeloperoxidase (MPO), has
been used recently in CD to study the mucosal inﬂamma-
tory reactivity to rectal gluten challenge [12]. Using the
same technique, about 50% of adult CD patients have
recently been reported to have a mucosal reactivity also to
cow’s milk protein (CM) [13]. We ourselves have observed
that 20% of patients with pSS and with the CD-associated
haplotype DQ2 have CD-like reactivity to rectal gluten
challenge without showing signs of CD [14]. We have
deﬁned such patients as being gluten sensitive with a
possible risk of developing CD at a later stage. In this
study, we report that pSS patients may have either an iso-
lated CM sensitivity or combined gluten–CM sensitivity.
In an attempt to elucidate the possible adverse effect of
CM sensitivity, we correlated the CM challenge results to
data from self-reported questionnaires about gastrointest-




Twenty-one adult patients (two males) with pSS according
to the revised American European Consensus Criteria were
included in this study [1]. Patients with secondary
Sj¨ ogren’s syndrome, previously diagnosed CD or IgE-type
reaction to CM were excluded. The patients were included
consecutively from the outpatient clinic at the Depart-
ment of Rheumatology, Uppsala University Hospital. The
mean age of the patients was 56 years (range 34–73) and
the median duration of sicca symptoms was 9 years (range
1–37). Eight of the patients also had other symptoms
besides sicca manifestations. One of the pSS patients had
high IgA antibody levels against gliadin, endomysium as
well as tissue-transglutaminase (tTG) and a duodenal
biopsy in this patient showed a total ﬂat mucosa consis-
tent with CD. Another patient had IgA deﬁciency but the
duodenal biopsy was normal. Three patients were treated
with corticosteroids in low dosages and four with chlor-
oquine phosphate. Eighteen adult healthy control subjects
(13 males) were included. The mean age of the control
subjects was 34 years (range 19–58). All participants were
asked about gastrointestinal symptoms, the existence of
eczema, allergic rhinitis, asthma or anaphylaxis and
self-experienced adverse food or drug reactions before
challenge studies. The pSS patients also answered a
questionnaire for support of the diagnosis of irritable
bowel syndrome (IBS) according to Rome III criteria [15].
The Ethics Committee of the Medical Faculty, Uppsala
University, approved the study. All the participants gave
their informed consent to participate in the study.
Serum antibodies to cow’s milk proteins
Serum IgA and IgG antibodies to casein, b-lactoglobulin
and a-lactalbumin were measured according to the man-
ufacturer’s instructions (Phadia AB, Uppsala, Sweden).
Human leucocyte antigen typing
The HLA-DQB1 typing was performed with PCR-SSOP
using the Luminex ﬂow bead platform (One Lambda Inc.,
Canoga Park, CA, USA) at the Department of Clinical
Immunology at our hospital.
Rectal challenge
The pSS patients and control subjects were challenged
with 6.5g dried milk powder (Semper AB, Stockholm,
Sweden) suspended in 25mL of 0.9% NaCl solution. The
solution was instilled into the rectum with a syringe with
the participant lying in the left lateral position. The
subjects were then allowed to move about as they wished
and were instructed to retain the enema for at least
60min. Rectal challenge was performed between 4 and
6p.m. and samplings were made 15h later, between 7 and
9a.m. The subjects were told to fast for 1h before and 1h
after the challenge and also from midnight until the
samplings were made. A placebo rectal challenge was
performed with 6.5g soya bean protein (Sigma-Aldric
Sweden AB, Stockholm) suspended in NaCl solution. The
patients were not on a speciﬁc diet and did not change
medication during the baseline and CM challenge studies.
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930 M. Lid´ en et alSubject preparation
All patients and controls were given a rectal enema (Klyx
120mL; Ferring, Copenhagen, Denmark) within 1h before
being tested with the rectal mucosal patch technique.
Mucosal patch technique and analytical measurements
The instrument used is a plastic catheter with a silicon
balloon at the end of the catheter. Three patches made of
highly absorptive cellulose material (Phadia AB) are
attached to the balloon. After the instrument is positioned
in the rectum with the subject lying in the left lateral
position with submaximal ﬂexed hips, the balloon is
inﬂated with air, bringing the patches in contact with the
mucosa for 20min. The balloon was then deﬂated and the
catheter was removed. The patches were cut off and
immediately placed into 2mL of 0.3% CTAB (N-cetyl-
N,N,N-trimethyl ammonium bromide; Merck, Darmstadt,
Germany) solution to extract the content. The extraction
solution was squeezed out of the patches, pooled, centri-
fuged and frozen at  70 1C. The extractionsolutions were
analysed for the concentrations of granule constituents
from neutrophils (MPO) and eosinophils (eosinophil
cationic protein; ECP) at the Department of Clinical
Chemistry, University Hospital, Uppsala. The intraindivi-
dual variation of separate measurements on two occasions
for 14 unchallenged individuals was on average 21% for
MPO (P=0.6) and 5% for ECP (P=0.80).
Air samples were collected with glass syringes during
deﬂation of the balloons and analysed for NO using a
chemiluminiscence NO analyser (Sievers NOA 280; Ionic
Instrument Business Group, Boulder, CO, USA) as
described previously [16].
Statistics and calculations
The results are presented as means and SD within brackets.
w
2 (between groups), Mann–Whitney U-test between
groups and Spearman’s rank correlation were used for
the statistical calculations.
Results
The results of rectal challenge with CM in patients with
pSS and healthy controls are presented in Fig. 1. The
ﬁgure shows the individual ﬁndings of the increase of
rectal mucosal NO and MPO concentrations (DNO and
DMPO) in the patient group and the healthy controls after
rectal CM challenge. As illustrated, 8/21 patients
(Po0.01, w
2 test) had a mucosal reaction to CM deﬁned
as the level of two SD above the mean of the control
subjects. No signiﬁcant increase of ECP was seen in either
patients or controls after challenge (data not shown). None
of the patients reacted to challenge with soya bean. No
relation to age and sex was seen in patients or controls.
The serum levels of IgA and IgG antibodies to casein,
b-lactoglobulin and a-lactalbumin were similar in the
patients with pSS compared with the controls (Mann–
Whitney U-test). Neither were any differences observed
between CM-reactive and non-reactive pSS patients
(Table 1). Fifty-two percent of our pSS patients had the
HLA alleles DQ2/DQ8. None had both haplotypes. Among
those who had a deﬁnite CM reactivity (n=8), three
patients were DQ2 positive and one was DQ8 positive. In
the group of 13 patients deﬁned as non-CM reactive, we
found seven DQ2-and DQ8-positive individuals. Thus, no
association between CM reactivity and these haplotypes
was seen. The patients of the present study had been
challenged previously with gluten and 5/21 were gluten
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Fig. 1.Increase ofrectal luminalnitricoxide(DNO)andmyeloperoxidase
(DMPO) in patients with primary Sj¨ ogren’s syndrome (pSS) after rectal
cow’s milkprotein (CM) challenge. The level of two SD above the mean of
the control subjects (n=18) is marked by a line (DMPO=49mg/L and
DNO=123p.p.b.)
Table 1. Mean serum levels (SD) of IgA and IgG antibodies to casein,
a-lactalbumin and b-lactoglobulin in patients with primary Sj¨ ogren’s
syndrome and healthy controls, with and without cow’s milk (CM)








IgG anti-casein (mg/L) 8.2 (7.9) 7.1 (4.6) 7.2 (7.1)
IgA anti-casein (mg/L) 1.7 (1.1) 1.9 (0.63) 2.8 (3.1)
IgG anti-a-lactalbumin (mg/L) 2.5 (0.3) 7.0 (12.2) 2.4 (0.7)
IgA anti-a-lactalbumin (mg/L) 1.1 (0.2) 1.4 (0.5) 1.2 (0.3)
IgG-b-lactoglobulin 11.1 (11.6) 12.9 (18.2) 4.2 (3.0)
IgA-b-lactoglobulin 1.4 (0.7) 1.7 (0.7) 1.2 (0.08)
SD, standard deviation.
  c 2008 The Authors
Journal compilation   c 2008 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 38:929–935
CM protein sensitivity assessed by the mucosal patch technique 931our patients were only gluten reactive (one of the
gluten-positive patients was diagnosed as having coeliac
disease), 5/21 were only CM reactive while 3/21 were both
gluten and CM reactive. The two patients with the
highest values of NO and MPO after CM protein challenge
were DQ2/DQ8 negative and had no reaction to gluten
challenge.
Allergic reactions (rhinitis, itching, urticaria, dyspnoea,
anaphylaxis) to intake of avocado, apple, peanut, straw-
berry and shellﬁsh or exposure to pollen, dust, furred
animals or mould were reported by 13/21 patients. Aller-
gic drug reactions (urticaria, itching, dyspnoea) were
frequently reported (n=9, 43%) and in particular against
antimicrobials and salicylates. Gastrointestinal symptoms
(obstipation, diarrhoea, ﬂatulence, pain, dyspepsia) were
reported by 16 patients (76%), and 10 patients (48%)
attributed such symptoms to an adverse food reaction
against particular CM products (n=5) and wheat gluten
(n=4). The ﬂow chart (Fig. 2) shows that the majority of
our patients who suspected CM intolerance were also in
fact reactive to rectal CM challenge. However, CM reac-
tivity also appeared in patients who had no suspicion of
food intolerance. Thirteen of our patients (62%) fulﬁlled
the criteria of IBS according to the Rome III criteria [15].
Four of them were classiﬁed as diarrhoea-predominant,
two as constipation-predominant, six with alternating
diarrhoea–constipation and one with unsubtyped IBS.
All patients except one with CM reactivity fulﬁlled the
criteria for diarrhoea-prominent or alternating IBS.
Those patients who were CM reactive were offered help
from a dietist to identify foods containing CM, and seven
patients excluded CM products for at least 6 months, and
six reported improved well-being and less abdominal
problems assessed by symptoms reported according to
the IBS protocol. One patient no more fulﬁlled the criteria
of IBS.
Discussion
In this study, we measured the local mucosal production
of NO and the mucosal release of MPO after instillation of
CM into the rectum of patients with pSS. The results were
obtained using a newly developed diagnostic system, the
mucosal patch technique [16, 17]. The major ﬁnding was
that rectal challenge with CM frequently induced a local
inﬂammatory mucosal reaction reﬂected by enhanced
mucosal NO production and MPO release in patients with
pSS but not in healthy controls. A minority of our pSS
patients was treated with low-dose corticosteroids, which
may have reduced an inﬂammatory response to CM. The
pronounced NO production observed in some of our pSS
patients is probably a result of activation of the major
inducible isoform of NO synthase NOS IIa [18], which
produces NO in high concentrations for as long as it is
activated due to inﬂammatory principles [19]. Gut muco-
sal granulocyte activation, deﬁned as MPO release, pre-
cedes NO production in patients with CD challenged with
gluten but, 15h after the challenge, we found both MPO
and NO responses [16]. Based on this knowledge, we
designed the timing of post-challenge measurements in
the present study. We found no increase in ECPconcentra-
tions after the challenge, suggesting an absence of eosi-
nophil activation induced by CM challenge, at least 15h
after challenge. The challenge and/or sampling proce-
dures have not caused the inﬂammatory response
observed because the CM challenge response was cor-
rected for baseline values and furthermore none of our
patients reacted to challenge with soyabean protein. Thus,
patients with pSS are obviously apt to react with a
mucosal inﬂammatory reaction due to the exposure of
not only gluten [14] but in particular CM.
The prevalence of all kinds of adverse reactions to food











































Fig. 2. Prevalence of self-reported food intolerance and suspected adverse reactions to cow’s milk protein (CM) in primary Sj¨ ogren’s syndrome (pSS)
patients and results of rectal challenge with CM.
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932 M. Lid´ en et alpopulation studies in Europe have assessed the prevalence
of adverse reactions to food and report a high frequency of
perceived food intolerance [7, 9]. In the United Kingdom,
20% of the population attributes atopic, intestinal and
joint symptoms and migraine to certain foods including
CM products and wheat. However, the results of double-
blind placebo-controlled food challenges (DBPCFC) esti-
mated the prevalence of adverse food reactions to be 1.8%
[7]. In a representative cross-sectional study in Germany,
the prevalence of all kinds of adverse reactions to food was
estimated to be 35% of the population [9].
One intriguing ﬁnding among our patients was the high
incidence of reported intestinal symptoms and in particu-
lar IBS-associated symptoms. IBS is considered to be a
functional bowel disorder with abnormal gut patterns of
motility, secretion and sensation with prevalence esti-
mates ranging from 10% to 20% [15, 20]. IBS has also
been reported to be associated with sicca complex, sicca
syndrome without an autoimmune component [21]. The
aetiology is largely unknown although different mechan-
isms for its symptoms have been proposed including
adverse food reactions to CM products [22–24]. Many of
our patients believed that dietary intolerance and in
particular intolerance to CM products contributed to their
intestinal symptoms. In fact, half of our patients with CM
sensitivity discovered by rectal challenge had suspected
that their gastrointestinal symptoms were an adverse CM
reaction (Fig. 2). In rigorous elimination diet studies in IBS
food intolerance is frequently reported [23, 25, 26], and
some patients with diarrhoea-predominant or alternating
bowel habit responded to an exclusion diet [26], but
attempts with various laboratory tests to identify non-IgE
food sensitivity have been disappointing [11].
The most common adverse reaction to CM is an IgE-
mediated allergy, at least in childhood, with a typical
clinical picture and a positive skin prick test and/or
increased IgE antibody levels to CM [27–29]. The non-
IgE-mediated food allergies are more difﬁcult to diagnose
and have until now required procedures with food elim-
ination and food challenges [30]. The best-known non-IgE
food protein-mediated immune damage is the gluten-
induced enteropathy seen in CD. Cow’s milk protein may
also induce – as observed among children – an entero-
pathy with more discrete histopathological ﬁndings com-
pared with CD [31, 32]. Many adult patients with CD do
not recover completely on a gluten-free diet [8], And the
question has been raised as to whether other food antigens
may contribute to their enteropathy and symptoms. In this
context, CM proteins have come into focus [33]. Recently,
we reported that rectal CM challenge in 40% of adult CD
patients on a gluten-free diet and without increased serum
antibodies to tTG and gliadin and various CM proteins
induced an inﬂammatory reaction similar to that pro-
duced by gluten [13]. This ﬁnding has led to the possibility
that CM sensitivity may contribute to persistent intestinal
symptoms in some celiac patients despite a gluten-free
diet. Our observed association between CM sensitivity and
IBS-like symptoms in our pSS patients may suggest that
food allergy against CM might play a role in their
intestinal symptoms. The pathways by which mucosal
inﬂammation is induced by rectal challenge with gluten
and CM in CD or pSS have not been identiﬁed until now.
In contrast, the pathophysiology of CD is well character-
ized. tTG 2 has been identiﬁed as the auto antigen in CD
and IgA anti-tTG autoantibodies are very sensitive and
speciﬁc markers for this disease. However, both the
expression of CD and the serum antibodies to tTG are
strictly dependent on dietary exposure to gluten. Activa-
tion of the adaptive immune system is one pre-requisite
for the occurrence of CD and is reﬂected by the develop-
ment of gliadin and tTG antibodies [34]. Recently, it has
been demonstrated that certain gluten peptides may also
elicit an innate immune response [35, 36]. One may
suspect that an innate immune response is a more promi-
nent factor behind the mucosal inﬂammation induced by
rectal CM and gluten challenge in patients with pSS
because they have no increased serum antibody levels
against gliadin [14] or immunogenic CM. The same is true
for the CM reactivity in celiac patients because they also
have normal levels of IgG/IgA antibodies against CM
proteins [13]. Celiac disease is strongly associated with
the HLA alleles DQ2/DQ8. Those patients with pSSwho are
gluten sensitive but not suffering from CD also carry these
alleles [14]. However, the present ﬁndings in pSS patients
show that CM sensitivity is not associated with DQ2/DQ8,
suggesting that additional genes may relate to CM
sensitivity.
The high prevalence (65%) of various allergic manifes-
tations and in particular allergic drug reactions (46%)
have been reported previously in pSS patients [5, 6]. In the
present study, our observations are in accordance with
such ﬁndings. The high propensity in pSS to any kind of
allergy including CM and gluten sensitivity may reﬂect an
allergic hypersensitivity that may be primarily due to
genetic factors or secondarily induced by the pSS disease
process. Nevertheless, our anecdotal results after CM
withdrawal merit further research on the possible impact
of adverse food reactions on symptoms and perhaps
disease activity in pSS. Hopefully, future studies, which
will require inter alia DBPCFC, will support our expecta-
tion that the rectal challenge procedure may be of clinical
help to identify foods causing non-IgE-mediated adverse
reactions.
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